Episode 22 · March 25, 2024 · 18 min

22: Big announcement and Hepatic impairment studies (Ep. 22)

Speed

Today’s show is about hepatic impairment clinical studies. I cover the rationale behind evaluating hepatic impairment, common study designs, and key factors in the analysis and interpretation of the study results. I also share a huge announcement about Aplos NCA, a cloud-based solution for calculating NCA PK parameters. Use the link below to learn more about Aplos NCA.

Links discussed in the show:

FDA guidance
EMA guideline
Aplos Analytics website
You can connect with me on LinkedIn and send me a message
Send me a message
Sign up for my newsletter

Ep 24Apr 22, 202424 min
Choosing an absorption model (Ep. 24)
Today’s show discussed approaches for modeling absorption profiles. I discussed the rationale behind modeling absorption and then described some common models. These included first-order absorption,…
Ep 15Dec 11, 202326 min
QSP, PBPK, PKPD, PopPK … analysis abbreviation soup! (Ep. 15)
In today’s episode I cover 4 different modeling approaches: QSP, PBPK, PopPK, and PKPD. All of these are methods for analyzing data to predict either drug concentrations, or a response variable. But…
Ep 14Nov 27, 202320 min
Clinical Drug Interaction Studies (Ep. 14)
In today’s episode I covered the different types of drug interactions, followed by features of clinical drug evaluation studies recommended in the guidance. Then I will review recommendations for…

Never miss an episode

All episodes are free. Listen on your favorite platform.

22: Big announcement and Hepatic impairment studies (Ep. 22)

Related episodes

Choosing an absorption model (Ep. 24)

QSP, PBPK, PKPD, PopPK … analysis abbreviation soup! (Ep. 15)

Clinical Drug Interaction Studies (Ep. 14)

Never miss an episode